^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    RRM1 underexpression

    i
    Other names: Ribonucleotide Reductase Catalytic Subunit M1, Ribonucleoside-Diphosphate Reductase Large Subunit, Ribonucleoside-Diphosphate Reductase Subunit M1, Ribonucleotide Reductase M1 Polypeptide, RR1, Ribonucleotide Reductase Large Subunit, Ribonucleotide Reductase R1 Subunit, RIR1, rrm1
    Entrez ID:
    6240
    Related biomarkers:
    Expression
    CNA
    1year
    Morphological predictors of the efficacy of mitotane therapy in adrenocortical cancer (PubMed, Probl Endokrinol (Mosk))
    Consistent with the findings in our study, low expression of RRM1, CYP2W1 and SOAT1 was associated with worse DFS with antitumor therapy. The results of the work indicate the need to assess the levels of immunoreactivity of these markers in patients with ACC before starting treatment with mitotane in order to predict the efficiency of therapy.
    Journal
    |
    RRM1 (Ribonucleotide Reductase Catalytic Subunit M1) • CYP2W1 (Cytochrome P450 Family 2 Subfamily W Member 1)
    |
    RRM1 underexpression • RRM1 expression
    |
    Lysodren (mitotane)
    over1year
    SRRM1 promotes the proliferation, migration, and invasion of hepatocellular carcinoma cells by regulating the JAK/STAT signaling pathway. (PubMed, Tissue Cell)
    SRRM1 played a significant role in the proliferation, migration, invasion and apoptosis of HCC, and promoted cancer by regulating the JAK/STAT signaling pathway.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • JAK2 (Janus kinase 2) • CDH1 (Cadherin 1) • CASP3 (Caspase 3) • VIM (Vimentin) • CDH2 (Cadherin 2) • IL6ST (Interleukin 6 Signal Transducer)
    |
    RRM1 underexpression
    over2years
    Prospective Clinical Study of Postoperative Individualized Adjuvant Chemotherapy for Patients with Non-Small-Cell Lung Cancer Based on mRNA Expression of the Molecular Markers RRM1, TUBB3, and ERCC1. (PubMed, J Oncol)
    The control group randomly received chemotherapy with gemcitabine plus cisplatin or paclitaxel plus cisplatin. The selection of chemotherapy regimen based on mRNA expression of the RRM1, TUBB3, and ERCC1 genes may improve selection of candidate patients to receive clinical chemotherapy. However, large-scale prospective clinical studies are needed for in-depth investigation.
    Clinical • Journal
    |
    ERCC1 (Excision repair cross-complementation group 1) • TUBB3 (Tubulin beta 3 class III) • RRM1 (Ribonucleotide Reductase Catalytic Subunit M1)
    |
    RRM1 underexpression • RRM1 expression
    |
    cisplatin • gemcitabine • paclitaxel
    3years
    [VIRTUAL] High RRM1 expression as a potential poor prognosis factorin bladder cancer patients (AACR 2021)
    Our study demonstrated that high RRM1 expression may serve as a poor prognostic biomarker in BLCA patients. Moreover, our study suggested that BLCA patients with high RRM1 expression may benefit more from ICIs therapies than those with low RRM1 expression.
    Clinical • IO biomarker
    |
    IFNG (Interferon, gamma) • RRM1 (Ribonucleotide Reductase Catalytic Subunit M1)
    |
    RRM1 underexpression